Section Arrow
MESO.NASDAQ
- Mesoblast Limited
Quotes are at least 15-min delayed:2025/09/03 20:33 EDT
Regular Hours
Last
 12.88
-0.24 (-1.83%)
Day High 
13.06 
Prev. Close
13.12 
1-M High
16.375 
Volume 
366.33K 
Bid
12.5
Ask
12.58
Day Low
12.66 
Open
13.06 
1-M Low
12.81 
Market Cap 
1.68B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 15.19 
20-SMA 15.31 
50-SMA 13.82 
52-W High 22 
52-W Low
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.85/-0.78
Enterprise Value
1.75B
Balance Sheet
Book Value Per Share
4.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
17.20M
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
STTKShattuck Labs1.28+0.27+26.73%-- 
Quotes are at least 15-min delayed:2025/09/03 20:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.